Cureus · 2024
Unveiling the Role of Human PER3 Gene Polymorphism (rs57875989) as a Potential Risk Factor in Fibromyalgia Syndrome Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Parvez Sidrah, Dzupina Andrej, Fatima Ghizal, Fedacko Jan, Magomedova Aminat, Mehdi Abbas A
Аннотация
Purpose Fibromyalgia syndrome (FMS) presents a chronic pain condition affecting muscles and joints. Investigating circadian rhythms' disruption, integral to physiological responses, this study delves into the potential impact of PER3 CLOCK gene polymorphism (rs57875989) on FMS pathogenesis. Methods In this study, we investigated PER3 gene polymorphism in 100 FMS patients and an equal number of control individuals. The genotyping of the PER3 gene polymorphism was conducted using polymerase chain reaction (PCR) methodology. Subsequently, we evaluated the association between PER3 gene polymorphism and FMS susceptibility using odds ratios (ORs) and 95% confidence intervals (CIs) by comparing the genotype and allele frequencies of the PER3 gene polymorphism between FMS patients and controls. Results The PER3 gene revealed three genotypes: 4/4, 4/5, and 5/5, with allele frequencies showing significant associations between FMS patients and controls (p<0.05). Notably, PER3 gene polymorphism was linked to FMS development, particularly the 4/4 genotype versus the combined 4/5 and 5/5 genotypes (OR=2.85; 95% CI, 1.35-6.0; p=0.008). These findings suggest a potential role of PER3 gene variation as a genetic risk factor for FMS. Conclusion These findings reported a potential association between PER3 gene polymorphism and FMS, illuminating novel pathways for comprehending and addressing this complex condition. This study holds promise for advancing our understanding of FMS etiology and may inform the development of innovative management strategies tailored to individual genetic profiles, potentially leading to more effective treatments and improved outcomes for patients grappling with FMS.